株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳性麻痺:パイプライン分析

Cerebral Palsy - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 200937
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.48円で換算しております。
Back to Top
脳性麻痺:パイプライン分析 Cerebral Palsy - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 52 Pages
概要

脳性麻痺は、運動、学習、視聴覚、思考など脳や神経系の機能に関連する一群の障害であり、筋緊張、異常歩行、腕、膝の拘縮、つま先での歩行、構音障害、視聴覚の障害疼痛などの症状があります。治療法には、抗けいれん薬や筋弛緩薬の利用などがあります。

当レポートでは、世界における脳性麻痺治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

脳性麻痺の概要

治療薬の開発

  • 脳性麻痺向けパイプライン製品:概要
  • 脳性麻痺向けパイプライン製品:比較分析

脳性麻痺:開発中の治療薬:企業別

脳性麻痺:開発中の治療薬:大学・研究機関別

脳性麻痺:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

脳性麻痺:開発中の製品:企業別

脳性麻痺:開発中の製品:大学・研究機関別

脳性麻痺:治療薬開発に従事している企業

  • Allergan Plc
  • Cell Cure Neurosciences, Ltd.
  • Cellular Biomedicine Group, Inc.
  • CHA Bio & Diostech Co., Ltd.
  • Neuralstem, Inc.

脳性麻痺:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • NeurArrest
  • NSI-566
  • onabotulinumtoxin A
  • 脳性麻痺向け幹細胞治療
  • 脳性麻痺・全身性エリテマトーデス向け幹細胞治療
    • 製品概要
    • 作用機序
    • R&Dの進捗

脳性麻痺:最近のパイプライン動向

脳性麻痺:休止中のプロジェクト

脳性麻痺:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8945IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral Palsy - Pipeline Review, H1 2017, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walk on the toes, speech problems (dysarthria), hearing or vision problems and pain. Treatment includes anticonvulsants and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cerebral Palsy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cerebral Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 1 respectively.

Cerebral Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral Palsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cerebral Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cerebral Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cerebral Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral Palsy (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cerebral Palsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cerebral Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Cerebral Palsy - Overview
  • Cerebral Palsy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Cerebral Palsy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Cerebral Palsy - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Cell Cure Neurosciences Ltd
  • Cellular Biomedicine Group Inc
  • CHA Bio & Diostech Co Ltd
  • CytoDel LLC
  • GW Pharmaceuticals Plc
  • Medy-Tox Inc
  • Meridigen Biotech Co Ltd
  • Neuralstem Inc
  • Cerebral Palsy - Drug Profiles
  • botulinum toxin next generation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cyto-012 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nabiximols - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NeurArrest - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSI-566 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • onabotulinumtoxinA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Cerebral Palsy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Cerebral Palsy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cerebral Palsy - Dormant Projects
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cerebral Palsy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Cerebral Palsy - Pipeline by Allergan Plc, H1 2017
  • Cerebral Palsy - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
  • Cerebral Palsy - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Cerebral Palsy - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017
  • Cerebral Palsy - Pipeline by CytoDel LLC, H1 2017
  • Cerebral Palsy - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Cerebral Palsy - Pipeline by Medy-Tox Inc, H1 2017
  • Cerebral Palsy - Pipeline by Meridigen Biotech Co Ltd, H1 2017
  • Cerebral Palsy - Pipeline by Neuralstem Inc, H1 2017
  • Cerebral Palsy - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Cerebral Palsy, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top